Reclassifying Anaphylaxis to Neuromuscular Blocking Agents Based on the Presumed Patho-Mechanism: IgE-Mediated, Pharmacological Adverse Reaction or "Innate Hypersensitivity"?
ContributorsSpoerl, David; Nigolian, Haig ; Czarnetzki, Christoph; Harr, Thomas
Published inInternational Journal of Molecular Sciences, vol. 18, no. 6
Publication date2017
Abstract
Keywords
- Anaphylaxis/diagnosis/etiology/metabolism
- Cross Reactions/immunology
- Drug Hypersensitivity/diagnosis/etiology/metabolism
- Drug-Related Side Effects and Adverse Reactions/complications/immunology
- Humans
- Hypersensitivity
- Immediate/diagnosis/etiology/metabolism
- Immunity
- Innate
- Immunoglobulin E/immunology
- Mast Cells/immunology/metabolism
- Nerve Tissue Proteins/metabolism
- Neuromuscular Blocking Agents/administration & dosage/adverse effects
- Receptors
- G-Protein-Coupled/metabolism
- Receptors
- Neuropeptide/metabolism
- Skin Tests/methods
Affiliation entities
Citation (ISO format)
SPOERL, David et al. Reclassifying Anaphylaxis to Neuromuscular Blocking Agents Based on the Presumed Patho-Mechanism: IgE-Mediated, Pharmacological Adverse Reaction or ‘Innate Hypersensitivity’? In: International Journal of Molecular Sciences, 2017, vol. 18, n° 6. doi: 10.3390/ijms18061223
Main files (1)
Article (Published version)
Identifiers
- PID : unige:111064
- DOI : 10.3390/ijms18061223
- PMID : 28590439
ISSN of the journal1661-6596